All News

Many of the medications used in the treatment of erectile dysfunction have interactions with other medications, so it is crucial for pharmacists to carefully examine patient profiles to optimize therapy and ensure safety.

New study results focus on blood pressure, blood sugar, and cholesterol levels; body mass index; and smoking status when individuals have bipolar or schizoaffective disorder or schizophrenia.

Investigators also identified that a polymerase inhibitor with a unique modification largely resists its removal from the RNA by the exonuclease.

Pharmacy Times spoke with students at the Idaho State University College of Pharmacy and its partner program at the University of Alaska Anchorage College of Health.

Osimertinib (Tagrisso; AstraZeneca) is FDA approved for 3 unique cancer indications.

Leveraging automation capabilities and operational capacity at scale, they bridge gaps and mitigate the impact of disruptions.

Thirty minutes of day of movement, such as walking, can help break the cycle of inflammation that causes symptoms even 6 months later.

Pluvicto is indicated for the treatment of adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who were previously administered other anticancer therapies.

Bevacizumab (Avastin) is a vascular endothelial growth factor inhibitor indicated several cancer types.

Nasacort offers temporary relief of allergy symptoms, such as nasal congestion, sneezing, itchy and runny nose.

Patient-centered communication incorporates patients’ concerns, ideas, and abilities when developing a treatment plan.

The FDA recently approved cabotegravir 200 mg/mL and rilpivirine 300 mg/mL as a once-monthly treatment for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen.

Analysis of the trial show that intensifying the chemotherapy regimen allowed for elimination of radiation in 90% of pediatric patients with T-cell acute lymphoblastic leukemia.

Open to all health care professionals, the PQA meeting is a top forum for learning best practices and emerging trends in medication services, pharmacist-provided care and quality improvement initiatives.

Study suggests a link between vitamin D deficiency and COVID-19 severity and mortality.

It is critical for pharmacists to inquire about the use of e-cigarette or vaping products in patients that present with certain symptoms.

Results of an excess-deaths analysis show that 18.2 million individuals have likely died as a result of the pandemic.

Medication therapy management programs enhance communication, spur innovation.

Sandostatin treats severe diarrhea and flushing associated with metastatic carcinoid tumors, as well as treatment of acromegaly.

Acid controllers relieve heartburn associated with indigestion.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the understanding of malignant lymphomas’ pathobiology and relationship with the immune system evolved during her clinical and investigational research into the subject.

Previous research has shown that genetic factors contribute immensely to the risk of migraine.

Omnipod 5 allows patients with diabetes to receive 72 hours of continuous, automated insulin administration.

This month's featured products include treatments for insomnia, atopic dermatitis, and more.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses how the field of hematopathology has changed over the last decade.

Professional assistance programs provide pathway for health care professionals to return to practice following treatment for substance use disorder.

Pharmacy Times will be covering the upcoming Hematology and Oncology Pharmacy Association (HOPA) Association Annual Conference live in Boston, Massachusetts, taking place March 30 through April 2.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses next steps following the results of the phase 2 trial assessing niraparib on the treatment of patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.